Ablynx extends agreement with Wyeth

Article Type: Food Facts From: Nutrition & Food Science, Volume 38, Issue 3.

GHENT, Belgium, December 20, 2007 Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies^®, a novel class of antibody-derived therapeutic proteins, announced today that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year. Wyeth and Ablynx are collaborating to discover and develop novel Nanobody^®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies^® developed under the collaboration.